BR9914834A - Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese - Google Patents

Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese

Info

Publication number
BR9914834A
BR9914834A BR9914834-0A BR9914834A BR9914834A BR 9914834 A BR9914834 A BR 9914834A BR 9914834 A BR9914834 A BR 9914834A BR 9914834 A BR9914834 A BR 9914834A
Authority
BR
Brazil
Prior art keywords
bone
treatment agent
pathobolism
activity
intensify
Prior art date
Application number
BR9914834-0A
Other languages
English (en)
Inventor
Shinichi Mochizuki
Nobuaki Fujise
Chiharu Masuyama
Eisuke Tsuda
Kanji Higashio
Original Assignee
Snow Brand Milk Products Co Ltd
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd, Sankyo Co filed Critical Snow Brand Milk Products Co Ltd
Publication of BR9914834A publication Critical patent/BR9914834A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"AGENTE DE TRATAMENTO DE PATOBOLISMO óSSEO, E, MéTODO PARA INTENSIFICAR A ATIVIDADE DE FATOR INIBIDOR DE OSTEOCLASTOGêNESE" é provido um novo agente de tratamento de patobolismo ósseo. Um agente de tratamento de patobolismo ósseo compreendendo pelo menos uma substância selecionada no grupo que consiste de um fator inibidor de osteoclastogênese (OCIF), seus homólogos e suas variantes e um polissacarídeo ou seus derivados. Como polissacarídeo ou seus derivados podem ser usados heparina, sulfato de dextrano e similares. é provido agente de tratamento de patobolismo ósseo que tem excelente efeito terapêutico em patobolismos ósseos como osteoporose, hipercalcemia ou reumatismo articular crónico e persistência da atividade. O agente é útil como remédio.
BR9914834-0A 1998-10-28 1999-10-28 Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese BR9914834A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32287498 1998-10-28
PCT/JP1999/005963 WO2000024416A1 (fr) 1998-10-28 1999-10-28 Agents therapeutiques pour deformations osseuses

Publications (1)

Publication Number Publication Date
BR9914834A true BR9914834A (pt) 2001-08-14

Family

ID=18148585

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914834-0A BR9914834A (pt) 1998-10-28 1999-10-28 Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese

Country Status (21)

Country Link
US (1) US6919312B2 (pt)
EP (1) EP1127578A4 (pt)
JP (1) JP3860415B2 (pt)
KR (1) KR20010082272A (pt)
CN (1) CN1183961C (pt)
AU (1) AU755422B2 (pt)
BR (1) BR9914834A (pt)
CA (1) CA2347107A1 (pt)
CZ (1) CZ20011378A3 (pt)
HK (1) HK1042847A1 (pt)
HU (1) HUP0104126A3 (pt)
IL (1) IL142557A0 (pt)
MX (1) MXPA01004225A (pt)
NO (1) NO20012106L (pt)
NZ (1) NZ511506A (pt)
PL (1) PL347559A1 (pt)
RU (1) RU2223782C2 (pt)
TR (1) TR200101146T2 (pt)
TW (1) TW529954B (pt)
WO (1) WO2000024416A1 (pt)
ZA (1) ZA200103296B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
MXPA01004225A (es) 1998-10-28 2002-06-04 Snow Brand Milk Prod Co Ltd Agente para el tratamiento del patobolismo de huesos.
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
EP1757619B1 (en) 2001-04-03 2010-02-17 Société des Produits Nestlé S.A. Osteoprotegerin in milk
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
AU2003208621A1 (en) * 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition
TW200400830A (en) * 2002-06-07 2004-01-16 Sankyo Co A pharmaceutical composition used in the treatment of bone erosion
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
JPWO2008041774A1 (ja) * 2006-10-02 2010-02-04 独立行政法人物質・材料研究機構 骨伝導能を有する徐放性製剤
CA2642940A1 (en) * 2006-12-22 2008-07-03 Mathys Ag Bettlach Precursor for the preparation of a pasty bone replacement material by admixture of a liquid
SG181615A1 (en) * 2009-12-09 2012-07-30 Agency Science Tech & Res Glycosaminoglycan mixtures
CN111454899B (zh) * 2020-04-30 2021-04-20 青岛思拓新源细胞医学有限公司 角叉菜多糖在抑制间充质干细胞成脂转化中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2604135B2 (ja) * 1986-02-28 1997-04-30 ライオン株式会社 口腔骨疾患治療剤
IL91438A (en) * 1989-08-25 1995-03-30 Bukh Meditec Preparation for treating dental disease
TW318142B (pt) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
RU2238949C2 (ru) 1997-04-15 2004-10-27 Санкио Компани Лимитед Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты)
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
CN1183159C (zh) 1997-09-24 2005-01-05 三共株式会社 破骨细胞形成抑制因子单克隆抗体、其用途和试剂盒
WO1999065916A1 (en) 1998-06-15 1999-12-23 Takeda Chemical Industries, Ltd. Thienodipyridine derivatives, production and use thereof
MXPA01004225A (es) 1998-10-28 2002-06-04 Snow Brand Milk Prod Co Ltd Agente para el tratamiento del patobolismo de huesos.
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
CN1345246A (zh) * 1999-09-03 2002-04-17 安姆根有限公司 预防或治疗癌症及与癌症相关的骨损失的组合物和方法
WO2001044472A1 (en) 1999-12-16 2001-06-21 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
AU2003208621A1 (en) 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition

Also Published As

Publication number Publication date
PL347559A1 (en) 2002-04-08
CN1325310A (zh) 2001-12-05
AU755422B2 (en) 2002-12-12
NO20012106D0 (no) 2001-04-27
KR20010082272A (ko) 2001-08-29
TW529954B (en) 2003-05-01
TR200101146T2 (tr) 2001-09-21
ZA200103296B (en) 2001-10-25
AU6487799A (en) 2000-05-15
CN1183961C (zh) 2005-01-12
CZ20011378A3 (cs) 2001-10-17
MXPA01004225A (es) 2002-06-04
RU2223782C2 (ru) 2004-02-20
IL142557A0 (en) 2002-03-10
US6919312B2 (en) 2005-07-19
NZ511506A (en) 2004-02-27
CA2347107A1 (en) 2000-05-04
HUP0104126A3 (en) 2004-07-28
NO20012106L (no) 2001-06-21
HUP0104126A2 (hu) 2002-03-28
EP1127578A1 (en) 2001-08-29
US20010031725A1 (en) 2001-10-18
JP3860415B2 (ja) 2006-12-20
HK1042847A1 (zh) 2002-08-30
EP1127578A4 (en) 2004-12-15
WO2000024416A1 (fr) 2000-05-04

Similar Documents

Publication Publication Date Title
BR9914834A (pt) Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese
BR0014384A (pt) Compostos para o tratamento da isquémia
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR9804437A (pt) Compostos para a osteoporose
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
CO5090836A1 (es) 3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcio
NO972043L (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
BR9911993A (pt) Método de desinfecção, volume desinfetado, composição desinfetante, névoa desinfetante e artigo desinfetado e aparelhagem para desinfecção
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
BR9906372A (pt) Composição farmaceutica aquosa para aplicação na mucosa
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
GT199800083A (es) Agonistas de prostaglandinas.
BR0010808A (pt) Composições farmacêuticas e usos
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
BR9810832B1 (pt) composição farmacêutica contendo como princìpios ativos vitamina d associada a um sal de cálcio, e, processos para a preparação de uma composição farmacêutica, para o tratamento de deficiências nutricionais de cálcio e vitamina d na velhice e para reduzir a perda de tecido ósseo ligada à idade e para evitar fraturas femurais e outras fraturas não vertebrais.
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR0109602A (pt) Glóbulos de liberação controlada contendo estavudina
BR0209856A (pt) Método para a destruição de oocistos
BRPI0015939B8 (pt) sistema terapêutico transdérmico com estabilidade aperfeiçoada e processo para a sua preparação
BR9808430A (pt) Método para melhorar a especificidade da regulação de gens em um organismo transformado
DE60334711D1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
BR9811843A (pt) Sistema de agente de consevação para produtos de tratamento corporal
BR0202439A (pt) Complexo, método para prolongar o tempo que o ocif ou um seu análogo ou variante fica retido na corrente sang ìnea, composição farmacêutica, uso de um complexo, e, método para a preparação de um complexo

Legal Events

Date Code Title Description
PC Transfer

Free format text: SANKYO COMPANY, LIMITED (JP)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1999 DE 28/04/2009.